ArticleJournal of neuroendocrinology2025
Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs.
Article in Journal of neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Article
- Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs.Journal of neuroendocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
To evaluate a radiomic strategy for predicting progression in advanced gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients treated with somatostatin analogs (SSAs). Fifty-eight patients with GEP-NETs and liver metastases, with baseline computerized tomography (CT) scans from June 2013 to November 2020, were studied retrospectively. Data collected included progression-free survival (PFS), overall survival (OS), tumor grading, death, and Ki67 index. Patients were categorized into progressive and non-progressive groups. Two radiologists performed 3D liver segmentation on baseline CT scans using 3DSlicer v4.10.2. One hundred six radiomic features were extracted and analyzed (T-test or Mann-Whitney). Radiomic feature efficacy was evaluated via receiver operating characteristic curves, and both univariate and multivariate logistic regression were used to develop predictive models. A significance level of p < .05 was maintained. Of 55 patients, 38 were progressive (median PFS and OS: 14 and 34 months, respectively), and 17 were non-progressive (median PFS and OS: 58 months each). Six radiomic features significantly differed between groups (p < .05), with an area under the curve (AUC) range of 0.64-0.74. Ki67 was the only clinical parameter significantly associated with progression risk (odds ratio (OR) = 1.14, p < .05). The combined radiomic features and Ki67 model proved most effective, showing an AUC of 0.814 (p = .008). The radiomic model alone did not reach statistical significance (p = .07). A combined model incorporating radiomic features and the Ki67 index effectively predicts disease progression in GEP-NET patients eligible for SSA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.